| 000 | 01844 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514004115.0 | ||
| 264 | 0 | _c20010809 | |
| 008 | 200108s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGiles, F J | |
| 245 | 0 | 0 |
_aMylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. _h[electronic resource] |
| 260 |
_bCancer _cJul 2001 |
||
| 300 |
_a406-13 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAminoglycosides |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 |
_aHepatic Veno-Occlusive Disease _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aKantarjian, H M | |
| 700 | 1 | _aKornblau, S M | |
| 700 | 1 | _aThomas, D A | |
| 700 | 1 | _aGarcia-Manero, G | |
| 700 | 1 | _aWaddelow, T A | |
| 700 | 1 | _aDavid, C L | |
| 700 | 1 | _aPhan, A T | |
| 700 | 1 | _aColburn, D E | |
| 700 | 1 | _aRashid, A | |
| 700 | 1 | _aEstey, E H | |
| 773 | 0 |
_tCancer _gvol. 92 _gno. 2 _gp. 406-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u _zAvailable from publisher's website |
| 999 |
_c11394444 _d11394444 |
||